Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008110Source: DataRank Database

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma is a research paper published in Journal for ImmunoTherapy of Cancer (2024). On theSindex it has a DataRank of 0.309. It has been cited 5 times, with 3 citing works in its 1-hop citation network.

N/A

0.309DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access5 citations · 3 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02655458

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (20 grants)OA: goldTopics (43)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 87%Citation Network 13%

Base Score Contribution

0.269

From this paper's citation signal

Citation Network Contribution

0.0398

From 3 citing papers with measurable signal

Learn more about DataRank methodology →

Top 3 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 3 citers.

CCL2 mediated IKZF1 expression promotes M2 polarization of glioma-associated macrophages through CD84-SHP2 pathway
Oncogene202416 citations92 referencesContributes 0.031
Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
Bioactive Materials202425 citations268 referencesContributes 0.012
SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy
Molecular Cancer20252 citations281 referencesContributes 0.004

Authors (13)

Keren Osman,Adolfo Aleman ORCID,Selma Bekri ORCID,Simone Kats ORCID,Amishi Dhadwal

Live enrichment

PubMed:38609316

Division of Cancer Prevention, National Cancer Institute

Grant: CA196521

Division of Cancer Prevention, National Cancer Institute

Grant: CA224319

Division of Cancer Prevention, National Cancer Institute

Grant: CA271390

Bristol-Myers Squibb

Grant: N/A

NIH/NIDDK

Grant: DK124165

NIH/NCI

Grant: RO1CA244899

NIH/NCI

Grant: RO1CA252222

NIH/NCI

Grant: UH2CA271390

National Institutes of Health

Grant: 1P30CA196521-01

Mouse Genetics

National Institutes of Health

Grant: 1R01CA244899-01A1

Development of a multi-omic clinical decision platform to guide personalized therapy

National Institutes of Health

Grant: 5U24CA224319-04

High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials

National Institutes of Health

Grant: 5U01DK124165-02

Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients

National Institutes of Health

Grant: 1R01CA252222-01

Targeting SOX11 in Mantle Cell Lymphoma

National Institutes of Health

Grant: 1UH2CA271390-01A1

Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients

NCI NIH HHS

Grant: U24 CA224319

NIDDK NIH HHS

Grant: U01 DK124165

NCI NIH HHS

Grant: R01 CA252222

NCI NIH HHS

Grant: UH3 CA271390

NCI NIH HHS

Grant: R01 CA244899

NCI NIH HHS

Grant: P30 CA196521

goldLicense: cc-by-nc

publisherhttps://jitc.bmj.com/content/jitc/12/4/e008110.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2023-008110

repositoryhttps://escholarship.org/content/qt8pw9f5cc/qt8pw9f5cc.pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11029259/pdf/jitc-2023-008110.pdf

https://doi.org/10.1136/jitc-2023-008110

Fields of Study

03 medical and health sciences0302 clinical medicineHumansLenalidomideMultiple MyelomaHematopoietic Stem Cell TransplantationLeukocytes, MononuclearTransplantation, AutologousStem Cell TransplantationTumor MicroenvironmentAntibodies, Monoclonal, Humanized

MeSH Terms

HumansLenalidomideMultiple MyelomaHematopoietic Stem Cell TransplantationLeukocytes, MononuclearTransplantation, AutologousStem Cell TransplantationTumor MicroenvironmentAntibodies, Monoclonal, Humanized

Keywords

Mononuclear610Antibodies, Monoclonal, HumanizedTransplantation, AutologousAntibodiesMonoclonalLeukocytesTumor MicroenvironmentHumanshematologic neoplasmsHumanizedLenalidomideRC254-282Clinical/Translational Cancer ImmunotherapyTransplantationHematopoietic Stem Cell TransplantationNeoplasms. Tumors. Oncology. Including cancer and carcinogensLeukocytes, Mononuclearimmunotherapytransplantation immunologyMultiple MyelomaAutologousStem Cell Transplantation

Sustainable Development Goals

SDG 3: 3. Good health